KDC-MN-342 – Kodiac biolabs

Plain-language summaryIntrigue 44 / 100

Bufotenin is the 5-hydroxyl version of N,N-DMT, found in Anadenanthera seeds (used for the South American snuffs yopo and cohoba) and in Bufo amphibian secretions. The hydroxyl group hurts blood-brain barrier penetration, so peripheral serotonin-like effects (vasoconstriction, nausea, sweating) tend to dominate any central activity. Whether bufotenin produces a meaningful psychedelic experience by typical routes is contested in the literature, with intramuscular and pulmonary routes producing variable reports. The compound is important historically and ethnobotanically but is rarely used in modern psychedelic research because of the awkward pharmacokinetic profile. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

35/100

A structural curiosity with real SAR probe value but weak evidence and negligible translational path

Look, bufotenin is one of those compounds that tells you more about other compounds than it does about itself. The whole point of 5-HO-DMT in a serious research context isn’t that it’s going to become a drug or even a useful therapeutic probe in its own right. It’s that the 5-hydroxy group is exactly what you reach for when you want to understand what that modification does to a tryptamine. Compared to N,N-DMT, it has substantially poorer blood-brain barrier penetration because the 5-OH group increases polarity and reduces central distribution. That’s the mechanism story, and honestly, it’s a useful story for structure-activity work even if it’s not exciting in isolation.

The pharmacology shifts toward peripheral 5-HT receptor effects: cardiovascular, sympathomimetic. That distinction between central psychedelic activity and peripheral serotonergic signaling is genuinely relevant to anyone doing tryptamine SAR, and bufotenin is the reference comparator you use to make that case. We like that it’s a clean chemical tool in that narrow context. What we don’t like is that the human data is essentially uninterpretable. The 1950s and 1960s studies, Fabing and Hawkins’ original 1956 prison-population work included, are so confounded by route of administration, dose uncertainty, and cardiovascular toxicity signals that its psychoactivity in humans remains an open and mostly uninteresting question. Whether the compound produces central effects or whether the reported effects were largely peripheral and toxic is still not resolved cleanly, and thats not a gap that’s attracting serious modern funding.

The 5-HT2A agonism is well-defined in vitro. The binding affinity is real and the molecular target is not in dispute. But in the tryptamine space right now, the serious research energy is going toward psilocybin, DMT, and next-generation psychoplastogens with neuroplasticity signals. Bufotenin isn’t part of that conversation. It’s Schedule I in the US, which limits what you can do with it, and it hasn’t generated a clinical-stage program anywhere that we can find. The compound is essentially a historical reference and a SAR anchor.

For a tryptamine lab running comparative pharmacology, bufotenin has real but narrow utility. You’d use it to make the case about the 5-OH modification’s effects on CNS penetration and receptor selectivity profile. Outside of that specific application, the evidence is too old, too methodologically weak, and too peripheral-focused to generate research excitement. Bench value is solid in its lane. Everything else is mediocre to poor. That’s what a 35 looks like.

Novelty: 35
Mechanism promise: 38
In-category differentiation: 42
Evidence quality: 25
Translational signal: 20
Research bench value: 50

Rationale Bufotenin sits at an awkward intersection: it’s chemically informative as a tryptamine comparator (the 5-OH group is exactly what you study to understand BBB penetration and peripheral vs. central 5-HT2A effects), but the human evidence base is a mess of confounded 1950s trials and the compound has generated no serious clinical interest. Schedule I cap at 65 doesn’t bind because the raw score is already 35.

Tryptamine / 5-HT2A agonist

5-hydroxy-N,N-dimethyltryptamine; a tryptamine related to DMT and serotonin; found in Anadenanthera seeds and toad secretions.

Abstract

Bufotenin (5-hydroxy-N,N-dimethyltryptamine, 5-HO-DMT; CAS 487-93-4; molecular formula C12H16N2O; molecular weight 204.27) is a tryptamine isolated from Anadenanthera seeds (used for South American snuffs called yopo and cohoba) and from Bufo amphibian secretions. Structurally bufotenin is the 5-hydroxy analog of N,N-DMT and the N,N-dimethyl analog of serotonin. Pharmacology: 5-HT2A agonism with poor blood-brain barrier penetration owing to the polar 5-hydroxy group; the central versus peripheral effect ratio is shifted toward peripheral 5-HT effects (cardiovascular, sympathetic) compared to DMT. The compound’s psychoactivity in humans has been debated for decades, with some 1950s and 1960s studies reporting psychotic-like effects (confounded by toxicity) and other studies suggesting limited central activity. Schedule I in the US. Used as a research probe for 5-HT2A pharmacology and as a comparator to DMT in tryptamine structure-activity studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-342Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-342

Bufotenin

Abstract

Read the full monograph